Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies

The development of drugs to improve cognition in patients with schizophrenia is a major unmet clinical need. A number of promising compounds failed in recent clinical trials, a pattern linked to poor translation between preclinical and clinical stages of drug development. Seeking proof of efficacy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Koychev, I, Joyce, D, Barkus, E, Ettinger, U, Schmechtig, A, Dourish, C T, Dawson, G R, Craig, K J, Deakin, J F W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070057/
https://www.ncbi.nlm.nih.gov/pubmed/27187233
http://dx.doi.org/10.1038/tp.2016.64

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070057/
https://www.ncbi.nlm.nih.gov/pubmed/27187233
http://dx.doi.org/10.1038/tp.2016.64

Ejemplares similares